Small airway function measured using forced expiratory flow between 25% and 75% of vital capacity and its relationship to airflow limitation in symptomatic ever-smokers: a cross-sectional study

Nowaf Y Aloiaidi, Mohammed Almeshari, James Stockley, Robert Andrew Stockley, Elizabeth Sapey

ABSTRACT

Background Chronic obstructive pulmonary disease (COPD) is diagnosed and its severity graded by traditional spirometric parameters (forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) and FEV1, respectively) but these parameters are considered insensitive for identifying early pathology. Measures of small airway function, including forced expiratory flow between 25% and 75% of vital capacity (FEF25-75), may be more valuable in the earliest phases of COPD. This study aimed to determine the prevalence of low FEF25-75 in ever-smokers with and without airflow limitation (AL) and to determine whether FEF25-75 relates to AL severity.

Method A retrospective analysis of lung function data of 1458 ever-smokers suspected clinically of having COPD. Low FEF25-75 was defined by z-score ≤−0.8345 and AL was defined by FEV1/FVC z-scores ≤−1.645. The severity of AL was evaluated using FEV1, z-scores. Participants were placed into three groups: normal FEF25-75/no AL (normal FEF25-75/AL−); low FEF25-75/no AL (low FEF25-75/AL−); and low FEF25-75/AL (low FEF25-75/AL+).

Results Low FEF25-75 was present in 99.9% of patients with AL and 50% of those without AL. Patients in the low FEF25-75/AL− group had lower spirometric measures (including FEV1, FEF25-75, FVC and FEV1/FVC) than those in the normal FEF25-75/AL− group. FEF25-75 decreased with AL severity. A logistic regression model demonstrated that in the absence of AL, the presence of low FEF25-75 was associated with lower FEV1 and FEV1/FVC even when smoking history was accounted for.

Conclusions Low FEF25-75 is a physiological trait in patients with conventional spirometric AL and likely reflects early evidence of impairment in the small airways when spirometry is within the ‘normal range’. FEF25-75 likely identifies a group of patients with early evidence of pathological lung damage who warrant careful monitoring and reinforced early intervention to abrogate further lung injury.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Studies have demonstrated that small airway dysfunction is prevalent in chronic obstructive pulmonary disease (COPD) and can be seen in some susceptible individuals without airflow limitation (AL), but studies using forced expiratory flow between 25% and 75% of vital capacity (FEF25-75) as measure of small airways function have generally included only a small number of patients with or at risk of developing COPD.

WHAT THIS STUDY ADDS

⇒ Low FEF25-75 is present in essentially all of patients with AL and detected in 50% of those without AL, which was associated with lower lung function indices than those with normal spirometry. This highlights that low FEF25-75 is a physiological feature in patients with AL and likely signifies earlier lung injury in the small airways before classical AL of COPD is present.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Low FEF25-75 without AL might detect a group of patients at risk of developing COPD, where evidence-based preventative strategies could be emphasised and implemented, thereby avoiding progressive lung damage.
FEV₁ % predicted. Other bodies recommend using the lower limit of normal (LLN) based on z-scores for the ratio to define AL and stratify the severity of the disease as this is thought to be less biased at the extremes of age. COPD is a slowly progressive disease in most individuals and FEV₁/FVC and FEV₁ lack the diagnostic sensitivity to identify early lung pathology. As only a proportion of smokers develop COPD, identifying individuals with early lung damage who are most at risk of developing overt COPD would enable a focused effort to prevent pathological progression.

The role of small airways in COPD has been explored in several studies. Small airways loss precedes the development of emphysema and AL in pathological studies investigated by microcomputed tomographic radiology. Further, in a longitudinal study of alpha-1 antitrypsin deficiency (AATD) patients using forced expiratory flow between 25% and 75% of vital capacity (FEF25-75) as a measure of small airway, a reduced FEF25-75 without AL was associated with worse health status and a faster subsequent decline in FEV₁, and appeared to precede AL defined by spirometry. This, and other studies, suggest that measures of small airways function (SAF; especially FEF25-75) may be more sensitive to early damage than traditional spirometric measures. We hypothesised that low FEF25-75 would be ubiquitous in patients with AL, as this has been demonstrated to precede the development of AL. Furthermore, we hypothesised that patients with low FEF25-75 but without AL would have physiological indicators of the risk of developing AL, even after the correction for potential confounders such as smoking history.

The study had five main aims:
1. To investigate the prevalence of low FEF25-75 in cigarette smokers with and without AL.
2. To assess whether low FEF25-75 without AL was associated with lower lung function measurements within the normal range, which might reflect an increased risk for developing AL.
3. To assess the relationships between FEF25-75 and other spirometric measures.
4. To assess the relationships between FEF25-75 and AL severity in established COPD.
5. To determine whether the presence of low FEF25-75 without AL was associated with lower lung function measurements, even after correction for potential confounders.

METHODS

Study design and setting
This was a retrospective, cross-sectional study of anonymised data from patients known to have or suspected of having COPD who underwent routine pulmonary function test at University Hospitals Birmingham National Health Service Foundation Trust, UK. The study included data obtained between 1 January 2016 and 30 April 2021 and all patients who had lung function during this period were screened for inclusion.

Eligibility criteria
All participants attending for lung function within the study period with the following included:
1. Symptoms suggestive of COPD (breathlessness and/or a persistent cough).
2. Age 30 years or older.
3. ≥10 pack-years history of cigarette smoking.
4. Either a confirmed diagnosis or suspected of having COPD by a senior physician.
5. All traditional spirometric measures including FEF25-75 were reported.

Participants were excluded if they had COPD related to AATD, a history/diagnosis of other chronic lung diseases or significant structural changes in the lung (such as bronchiectasis) defined radiologically. Patients with emphysema identified radiologically; however, were not excluded.

Study measures
Patients’ demographic data were collected. Smoking history included smoking status at the time of testing (ex-smoker or current smoker), pack-years history and years since quitting smoking. The smoking exposure was categorised into light (<20 pack-year), moderate (20–40 pack-years) and heavy (>40 pack-year). Regular medication use was documented.

FEV₁, FVC, FEV₁/FVC, FEF25-75, FEV₁ in the first 3 s (FEV₃), and FEV₁/FVC were assessed. Corrected FEF25-75 for lung volume (FEF25-75/FVC) was also assessed. Lung function assessments used the Ultima PF Pulmonary Function System (Medical Graphics UK, Tewkesbury, UK) and were performed in accordance with national guidelines. In this study, predicted values for routine spirometric measures were derived from the European Community for Steel and Coal. The z-score for the routine spirometric measures were calculated using the Global Lung Function Initiative 2012 formula. The z-scores for FEF25-75 and FEV₁/FVC were used to define abnormality. A cut-off z-score for normality for FEF25-75 was chosen of −0.8435 as this has shown to predict COPD development. The LLN (ie, z-score −1.645) was used for FEV₁/FVC to define AL, as recommended in the American Thoracic Society/European Respiratory Society guidelines. Using these thresholds, participants were grouped into three groups: normal FEF25-75/ no AL (normal FEF25-75/AL−); low FEF25-75/ no AL (low FEF25-75/AL−); and low FEF25-75/ AL (FEF25-75/AL+). AL severity was defined using FEV₁ z-score, to classify five severity groups.

FEF25-75 z-score was compared with z-scores of other physiological measures where available.

Statistical analysis
Statistical analysis was performed using IBM SPSS software (V.26). Data were not normally distributed, hence...
Variables, which were associated with multicollinearity (defined by variable inflation factor (VIF) >10) with other variables, were not included in the multivariate logistic regression. A p<0.05 was considered statistically significant throughout. For group comparisons, p values were adjusted using the Benjamini-Hochberg method with adjusted p value significance level set at p<0.05. No power calculations were conducted for this pragmatic study.

Patient and public involvement

Patients and/or the public did not take part in the development, conduct, reporting or dissemination of this study.

RESULTS

Participant’s selection

On initial screening, the dataset included 2258 records. After assessing for eligibility, 1458 ever-smokers were included (see figure 1 for a flow chart including reasons for exclusion). These participants were placed into the three groups based on the predefined criteria: normal FEF 25–75/AL− group (n=316); low FEF 25–75/AL− (n=335) and low FEF 25–75/AL+ (n=806). One participant did not meet any of the grouping criteria and was therefore excluded from the final analysis.

Prevalence of low FEF 25–75

All but one participant with AL had low FEF 25–75 (806/807; 99.9%). Of those without AL, 51.4% (335/650) had low FEF 25–75.

Demographics and clinical characteristics

Baseline demographics for the eligible participants and groups are shown in table 1. The average age was higher in low FEF 25–75/AL+ group (median 65 years; IQR 58–73) vs both normal FEF 25–75/AL− group (median 63 years (IQR 54.75–72); p=0.012) and low FEF 25–75/AL− group (median 63 years (IQR 54.75–72); p=0.025). There were no differences in sex across groups. Body mass index (BMI) was lower (p<0.001) in low FEF 25–75/AL+ group than both normal FEF 25–75/AL− group (median BMI 25.67; IQR 21.88–29.82 vs 30.20; IQR 25.34–34.71) and low FEF 25–75/AL− group (median BMI 28.94; IQR 25.33–34.071).

Participants in normal FEF 25–75/AL− group had generally smoked less (less heavy smokers and a lower pack-year history) compared with low FEF 25–75/AL− group and low FEF 25–75/AL+ group, with no differences between the latter 2. Expectedly, patients in low FEF 25–75/AL+ group used more COPD-associated medications than those in normal FEF 25–75/AL− group or low FEF 25–75/AL− group, including short-acting beta-2 agonists (SABA), inhaled corticosteroids (ICS)/long-acting beta-2 agonists (LABA) and long-acting muscarinic antagonists (LAMA) (p<0.001 for all). Interestingly, participants in low FEF 25–75/AL− group used more COPD medications (including SABA and

Kruskal-Wallis H tests were used throughout with the median and IQR reported. Where Kruskal-Wallis H tests were significant, a Mann-Whitney U test was conducted. For variables used in group definitions (FEF 25–75), no statistical analysis was conducted, except where the definition did not cause the variable to differ. Here, Mann-Whitney U tests were performed to determine the differences. Categorical variables were assessed using χ² or Fisher’s exact test, with the count and percentage reported. The relationship of FEF 25–75 z-score with z-score of other physiological measures and whether smoking behaviours have impact on the relationships were assessed using weight least-square regression. Coefficient of determination (r²) was reported throughout. Curvilinear regression was used to determine the relationship between FEF 25–75 % predicted or FEF 25–75/FVC with % predicted or ratio of other physiological measures, with r² reported throughout.

Logistic regression was performed to identify factors associated with the presence of low FEF 25–75. χ² and Mann-Whitney U test were used to identify relevant univariable risk factors and significant variables were included in the univariate logistic regression and ORs with 95% CIs reported. Significant variables in univariate analyses were included in the subsequent multivariate analysis.

Figure 1 Flow chart of the retrospective study. This figure shows the selection of patients according to eligibility criteria. One participant did not meet any of the group definition and was therefore not included in the grouping analysis. AL, airflow limitation; COPD, chronic obstructive pulmonary disease; FEF 25–75, forced expiratory flow between 25% and 75% of vital capacity; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PPY, pack per year.

![Flow chart](Image)

Baseline demographics for the eligible participants and groups are shown in table 1. The average age was higher in low FEF 25–75/AL+ group (median 65 years; IQR 58–73) vs both normal FEF 25–75/AL− group (median 63 years (IQR 54.75–72); p=0.012) and low FEF 25–75/AL− group (median 63 years (IQR 54.75–72); p=0.025). There were no differences in sex across groups. Body mass index (BMI) was lower (p<0.001) in low FEF 25–75/AL+ group than both normal FEF 25–75/AL− group (median BMI 25.67; IQR 21.88–29.82 vs 30.20; IQR 25.34–34.71) and low FEF 25–75/AL− group (median BMI 28.94; IQR 25.33–34.071).

Participants in normal FEF 25–75/AL− group had generally smoked less (less heavy smokers and a lower pack-year history) compared with low FEF 25–75/AL− group and low FEF 25–75/AL+ group, with no differences between the latter 2. Expectedly, patients in low FEF 25–75/AL+ group used more COPD-associated medications than those in normal FEF 25–75/AL− group or low FEF 25–75/AL− group, including short-acting beta-2 agonists (SABA), inhaled corticosteroids (ICS)/long-acting beta-2 agonists (LABA) and long-acting muscarinic antagonists (LAMA) (p<0.001 for all). Interestingly, participants in low FEF 25–75/AL− group used more COPD medications (including SABA and

Alobaidi NY, et al. BMJ Open Resp Res 2022;9:e001385. doi:10.1136/bmjresp-2022-001385
ICS/LABA) than normal FEF_{25-75}/AL− group (p<0.001 for all). Details of the medications used across groups are provided in online supplemental table E1.

**Physiological assessment of lung function**

Table 2 shows the baseline spirometric measures for the three groups. All spirometric measures were lower in low FEF_{25-75}/AL− group than normal FEF_{25-75}/AL− group (p<0.001).

Participants in low FEF_{25-75}/AL+ group had lower lung function (p<0.001 for all comparisons) than both low FEF_{25-75}/AL− group and normal FEF_{25-75}/AL− group. FVC z-score and FVC % predicted did not differ between low FEF_{25-75}/AL+ group and low FEF_{25-75}/AL− group. The distribution of FEF_{25-75} z-score, FEV1 z-score, FVC/FVC z-score and FVC z-score across groups are shown graphically in figure 2. The distribution of FEV1/FVC z-score, FVC, FEV1 % predicted, FVC % predicted, FEV1/FVC ratio and FVC/FVC ratio across groups are shown in online supplemental figure E1.

**The relationship of FEF_{25-75} with AL severity**

Participants with AL were grouped according to AL severity. Table 3 summarises baseline demographics and measures of small airways of these participants. In this cohort, patients with very severe disease were younger than those with lesser severity (p<0.001 for all comparisons). There were no differences between subgroups for sex or ethnicity, although BMI was lower in patients with very severe disease compared with moderately severe patients (median BMI 23.43 (IQR 19.62–28.73) vs 26.99 (IQR 22.85–30.36), p=0.01). Of note, smoking status and pack-year history did not differ across severity groups but those with the most severe disease had stopped smoking later than the other groups.

FEF_{25-75} z-score worsened in a stepwise manner as the severity of AL increased (p<0.001; see figure 3). Of note, even in mild AL, FEF_{25-75} % predicted was substantially impaired (median 40.50% (IQR 33.74–48.48) and 41.93% (IQR 30.95–48.58) for FEF_{25-75}/FVC; see online supplemental figure E2).

**The relationship of FEF_{25-75} with other lung function parameters**

Including all participants (n=1458), FEF_{25-75} z-score demonstrated a strong relationship to FEV1 ($r^2=0.90$, p<0.001; see figure 4) and FEV1/FVC z-score ($r^2=0.86$, p<0.001; see figure 5), but a weaker relationship to FVC...
In the multiple regression analyses (n=1458; accounting for years since quitting smoking), pack-years was not a statistically significant predictor in any of the regression models.

In the multiple regression analysis for ex-smokers (n=616; accounting for years since quitting smoking), FEF25–75 z-score showed strong relationship to FEV1 z-score (r²=0.90, p<0.001) and FEV1/FVC (r²=0.86, p<0.001), and weak relationship to FVC z-score (r²=0.18, p<0.001). Pack-years was not a statistically significant predictor in any of the regression models.

In the multiple regression analysis for ex-smokers (n=616; accounting for years since quitting smoking), FEF25–75 z-score showed strong relationship to FEV1 z-score (r²=0.90, p<0.001) and FEV1/FVC (r²=0.86, p<0.001), and weak relationship to FVC z-score (r²=0.18, p<0.001). Pack-years was not a statistically significant predictor in any of the regression models.

The association of the presence of low FEF25–75 with low lung function measurements

A regression model was built to assess whether the presence of low FEF25–75, without AL was associated with lower lung function measurements (see table 4). In the univariate analysis, pack-years, sex, FEV1 z-score, FVC z-score and FEV1/FVC z-score were significant factors related to the presence of low FEF25–75. All significant variables were included in the multivariate analysis except FVC z-score because of multicollinearity with other spirometric measures (VIF=30.94). The multivariate analysis demonstrated that females had a 33.22 times higher OR of having low FEF25–75 compared with males (95% CI, 8.19 to 134.72). The multivariate analysis also showed that the presence of low FEF25–75 was associated with a lower FEV1 z-score and FEV1/FVC z-score even when in the normal range. Of the significant factors in univariate analysis, pack-years was no longer significant in the multivariate analysis.

DISCUSSION

This cross-sectional study of commonly measure of SAF (FEF25–75) in smokers suspected of having COPD highlights four important points.

First, low FEF25–75 (considered indicative of impairment in the small airways) is a constant feature of those who have developed AL, with and without correction for FVC. Second, there was a significant reduction in FEF25–75 even in mild AL, suggesting a substantial disruption of SAF prior to crossing the AL diagnostic criteria. Indeed, once AL is established, there is a strong association between FEF25–75 z-score across AL severity.

Third, evidence of low FEF25–75 is common (51.4%) in symptomatic ever-smokers even without AL and is
associated with lower lung function parameters (even while in the normal range) compared with those with normal FEF_{25-75} and normal FEV_{1}/FVC. This suggests that even when routine spirometry appears ‘normal’, those with low FEF_{25-75} may have physiological evidence suggesting decline compared with health. This group of patients likely have early lung injury reflecting small airway impairment. Our data support the notion that such patients may form a cohort that would benefit from close monitoring, to ascertain progression potentially leading to COPD and support to mitigate such an outcome.

Fourth, the relationship between FEF_{25-75} and FEV_{1} and FEV_{1}/FVC is maintained even following adjustment for smoking history, indicating it is independent of cigarette load. Further, the logistic regression demonstrated that the presence of low FEF_{25-75} was associated with lower FEV_{1} and FEV_{1}/FVC, after correcting for smoking status. This suggests there are a group of smokers who are pathophysiologically different, consistent with a ‘susceptible’ cohort. Further study is needed to understand the mechanisms underpinning this potential susceptibility.

In the regression model, sex was related to low FEF_{25-75} in the absence of AL, with females 33 times more likely to have low FEF_{25-75}, although with a wide 95% CI. In the AATD study by Stockley et al there was also a higher proportion of females with low FEF_{25-75} than males compared with those with normal spirometry and AL. This study and the AATD study highlight that females have a greater likelihood of a low FEF_{25-75} in the absence of AL. Given that females with COPD have greater small airway impairments than males and females are at higher risk of developing COPD than males with similar smoking histories, our finding and those of Stockley et al indicate that low FEF_{25-75} (which is likely suggestive of impairment in the small airways) is likely to be greater in females before developing overt AL. Studies have reported that females have small tracheal cross-sectional area compared with males. This may be similar throughout the bronchial tree explaining why females are most likely to have low FEF_{25-75} without AL than males. However, confirming this will require more comprehensive studies.

In the current study, age was higher in the low FEF_{25-75}/AL+ group than the normal FEF_{25-75}/AL− group and low FEF_{25-75}/AL− group, but was reduced in those with very severe AL compared with all other severities of AL. In a complex disease such as COPD, decline rates are variable. Age (as a surrogate of time) might account for some of the differences in baseline lung function between the

Figure 2  Distribution of spirometric measures across study groups. A box plot demonstrating the distribution of z-scores of spirometric measures across groups. The plot shows median, IQR, minimum and maximum. (A) The distribution of FEF_{25-75} z-score across groups. (B) The distribution of FEV_{1}/FVC z-score across groups. (C) The distribution of FEV_{1} z-score across groups. (D) The distribution of FVC z-score across groups. For figures (A, D), statistical test was only done for differences between groups where a definition did cause the variable to differ, and the reported p values are for the Mann-Whitney U test. For figures (B, C), the presented p values are for Mann-Whitney U test, and the Kruskal Wallis tests p values for both figures were<0.001. AL, airflow limitation; FEF_{25-75}, forced expiratory flow between 25% and 75% of vital capacity; FEV_{1}, forced expiratory volume in 1 s; FVC, forced vital capacity; NS, not significant.
Table 3  Baseline demographics and FEF<sub>25-75</sub> across AL severity

| Variable                  | Mild n=177 | Moderate n=111 | Moderately severe n=120 | Severe n=263 | Very severe n=135 |
|---------------------------|------------|----------------|-------------------------|--------------|-------------------|
| Age (years)               | 65 (57–75) | 67 (60–75)     | 67 (58.50–74)           | 69 (61–73)   | 59 (53–64)        |
| Sex (male: female) n      | 92: 86     | 50: 61         | 72: 48                  | 138: 125     | 73: 62            |
| Smoking status (n, %)     |            |                |                         |              |                   |
| Current smokers           | 113 (63.5) | 59 (53.2)      | 72 (60)                 | 159 (60.5)   | 79 (58.5)         |
| Ex-smokers                | 65 (36.5)  | 52 (46.8)      | 48 (40)                 | 104 (39.5)   | 56 (41.5)         |
| Pack-year                 | 40 (26.75–55) | 41 (25–53) | 43 (29–60)            | 44 (30–62)   | 38 (23–63)        |
| Years quit                | 12 (3–21.50) | 9 (3–16)     | 9 (2.25–19.50)          | 7 (3–14)     | 5 (2–10)*         |
| BMI (kg/m<sup>2</sup>)    | 25.78 (22.96–28.68) | 26.17 (21.29–30.42) | 26.99 (22.85–30.36) | 25.52 (21.92–30.66) | 23.43 (19.62–28.73) |
| FEF<sub>25-75</sub> z-score | -1.94 (-2.18 to -1.69) | -2.28 (-2.57 to -2.07)* | -2.56 (-2.82 to -2.32)*† | -3.01 (-3.26 to -2.78)*†‡ | -3.77 (-4.11 to -3.52)*†‡§ |
| % Predicted               | 40.50 (33.74 to 48.48) | 32.50 (26.49 to 38.56)* | 25.76 (21.40 to 29.61)*† | 17.60 (13.95 to 21.62)*†‡ | 10.32 (8.76 to 13.67)*†‡§ |
| FEF<sub>25-75</sub>/FVC   | 41.93 (30.95 to 48.58) | 38.11 (29.23 to 47.09) | 31.61 (24.04 to 40.27)*† | 23.28 (18.08 to 31.43)*†‡ | 15.68 (13.26 to 22.33)*†‡§ |

Data are presented as median and IQR unless otherwise stated. Severity of AL are stratified using FEV<sub>1</sub> z-score. In the groups’ comparisons, the significance level for adjusted p value was set at 0.05.

*Significantly different from mild.
†Significantly different from moderate.
‡Significantly different from moderately severe.
§Significantly different from severe.

AL, airflow limitation; BMI, body mass index; FEF25-75, forced expiratory flow between 25% and 75% of vital capacity; FEV3, forced expiratory volume in 3 s; FVC, forced vital capacity.
low FEF$_{25-75}$/AL$^-$ group and low FEF$_{25-75}$/AL$^+$ group. However, age was not a significant factor accounting for the presence of low FEF$_{25-75}$ in multivariate regression modelling. The contribution of ageing on the presence of low FEF$_{25-75}$ can only be confirmed by longitudinal follow-up, which would also need to understand the relationship between small and large airways function in COPD and might support new monitoring and treatment strategies.

Smoking exposure was similar between low FEF$_{25-75}$/AL$^-$ group and low FEF$_{25-75}$/AL$^+$ group and did not differ across increasing AL severity (as grouped by FEV$_1$ z-score) nor was associated with low FEF$_{25-75}$ in multivariate analysis. These results suggest that smoking exposure alone cannot explain the physiological differences between groups. Tsushima et al reported similar findings, demonstrating that smokers with COPD had similar pack-year history compared with those designated at-risk of COPD, although Mirsadraee et al suggested this reflected a lower smoke exposure. This latter study used GOLD criteria and % predicted to define groups while our study used the z-scores to define abnormality.

**Figure 3** Distribution of FEF$_{25-75}$ z-score across AL severity. A box plot demonstrating the distribution of FEF$_{25-75}$ z-score across AL severity. The plot shows median, IQR, minimum and maximum. AL severity was assessed using FEV$_1$ z-score. The presented p values are for Mann-Whitney U test, and the Kruskal Wallis tests p value was <0.001 for all. AL, airflow limitation; FEF$_{25-75}$, forced expiratory flow between 25% and 75% of vital capacity.

**Figure 4** FEV$_1$ z-score plotted against FEF$_{25-75}$ z-score. A scatter plot showing the relationship between FEF$_{25-75}$ z-score and FEV$_1$ z-score. The coefficient of determination ($r^2$) for the WLS regression is shown in the figure along with its p value. FEF$_{25-75}$, forced expiratory flow between 25% and 75% of vital capacity; FEV$_1$, forced expired volume in 1 s; WLS, weight-least square.

**Figure 5** FEV$_1$/FVC z-score plotted against FEF$_{25-75}$ z-score. A scatter plot showing the relationship between FEF$_{25-75}$ z-score and FEV$_1$/FVC z-score. The plot is divided according to groups definition. The coefficient of determination ($r^2$) for the WLS regression is shown in the figure along with its p value. AL, airflow limitation; FEF$_{25-75}$, forced expiratory flow between 25% and 75% of vital capacity; FEV$_1$, forced expired volume in 1 s; FVC, forced vital capacity; WLS, weight-least square.

**Figure 6** FEV$_3$/FVC plotted against FEF$_{25-75}$ z-score. A scatter plot showing the relationship between FEF$_{25-75}$ z-score and FEV$_3$/FVC. The coefficient of determination ($r^2$) for the WLS regression is shown in the figure along with its p value. FEF$_{25-75}$, forced expiratory flow between 25% and 75% of vital capacity; FEV$_3$, forced expired volume in 1 s; FVC, forced vital capacity; WLS, weight-least square.
Table 4 Logistic regression of the association of the presence of low FEV$_{25-75}$ with low lung function measurement in participants without AL.

| Variable                  | Univariate | Multivariate* |
|---------------------------|------------|---------------|
|                          | OR         | 95% CI        | P value | OR         | 95% CI        | P value |
| Age                       | 1.004      | 0.991 to 1.018 | 0.55     | 0.988      | 0.971 to 1.005 | 0.168   |
| Pack-years                | 1.009      | 1.003 to 1.015 | 0.002    | 0.988      | 0.971 to 1.005 | 0.168   |
| Smoking status†           |            |               |          |            |               |         |
| Current smokers           | 1.340      | 0.983 to 1.827 | 0.064    |            |               |         |
| Sex‡                      |            |               |          |            |               |         |
| Female                    | 1.383      | 1.016 to 1.883 | 0.039    | 33.225     | 8.194 to 134.723 | <0.001 |
| FEV$_1$ z-score           | 0.136      | 0.100 to 0.185 | <0.001   | 0.001      | 0.00008 to 0.005 | <0.001 |
| FEV$_1$/FVC z-score       | 0.043      | 0.027 to 0.068 | <0.001   | 0.00001    | 0.00001 to 0.0003 | <0.001 |
| FVC z-score               | 0.449      | 0.377 to 0.536 | <0.001   |            |               |         |

This tables demonstrate the logistic regression of the association of the presence of low FEV$_{25-75}$ with low lung function measurements in participants without AL ($n=651$ (those normal FEV$_{25-75}$ $n=316$ vs those with low FEV$_{25-75}$ $n=335$)).

Low FEV$_{25-75}$ was defined by z-score<−0.8435. Statistically significant p values are written in bold.

*The multivariate regression model showed a Nagelkerke $R^2=0.942$ and Hosmer-Lemeshow p value=0.999.
†The reference category was ex-smokers.
‡The reference category was male.

AL, airflow limitation; BMI, body mass index; FEV$_{25-75}$, forced expiratory flow between 25% and 75% of vital capacity; FEV$_1$, forced expiratory volume in 1 s; FVC, forced vital capacity.

in FEV$_1$/FVC and FEV$_{25-75}$. The physiological criteria used may account for some differences in study findings.

The FEV$_1$/FVC has been used to detect mild lung injury in the absence of AL. Morris et al reported that, compared with those with normal FEV$_1$/FVC, patients with a lower ratio had lower FEV$_1$, higher residual volume (RV)/total lung capacity (TLC), higher RV, higher TLC and lower transfer factor for carbon monoxide (TLco), potentially highlighting the presence of early physiological impairment including air trapping and impaired gas exchange. Our study demonstrated that FEV$_1$/FVC was lower (although within normal range) in the low FEV$_{25-75}$/AL− group than in normal FEV$_{25-75}$/AL− group and was strongly associated with the FEV$_{25-75}$ z-score, providing further support that the FEV$_{25-75}$ z-score is likely detecting early lung pathology in this group. FEV$_{25-75}$/FVC has also been used in the early detection of COPD and again this measure was also lower in low FEV$_{25-75}$/AL− group, further supporting the FEV$_{25-75}$ z-score.

This study found that the use of ICS/LABA was as high in the low FEV$_{25-75}$/AL− group as in the low FEV$_{25-75}$/AL+ group, despite no AL in former group. This contradicts the recommendation by NICE guidelines that the use of ICS/LABA should be for those with spirometrically defined AL. Therefore, the absence of AL in low FEV$_{25-75}$/AL− group raises concern regarding the reason for prescribing such high levels of ICS/LABA. ICS/LABA combinations contain high dose of ICS characterised by high potency, and adverse effects, including community-acquired pneumonia, glucose dysregulation and adrenal suppression. There are two possible reasons why patients in low FEV$_{25-75}$/AL− group are prescribed ICS/LABA. First, the current study used the LLN to define AL, whereas the fixed 70% cut-off is still widely used in clinical practice. This could explain that some patients were given ICS/LABA following the confirmation of AL using the fixed ratio cut-off. Second, given the lack of evidence on how to treat patients with symptoms of COPD despite no AL, the patients might have experienced worse respiratory symptoms, requiring physicians to escalate therapy, by the addition of ICS. Whether using COPD medications (and especially ICS) to treat patients without AL is of benefit in the patients described here, requires appropriate randomised control trials. An RCT by Han et al is ongoing, which evaluates using LABA/LAMA in patients with COPD symptoms but no AL to determine whether such medication is effective in such patients and the same should be done with ICS.

Several studies have assessed FEV$_{25-75}$ in COPD. FEV$_{25-75}$ % predicted was lower (though not necessarily abnormal) in patients at risk of developing COPD. Correction of FEV$_{25-75}$ for FVC also identifies early pathological changes prior to COPD development and expiratory flow rates (including FEV$_{25-75}$) detected abnormality in those with normal FEV$_1$/FVC. Our findings, together with other studies strengthen FEV$_{25-75}$ (expressed as either % predicted or z-score) as a valuable marker of impairment in the small airways before classically defined AL is present.

Concerns about the use of FEV$_{25-75}$ in clinical management have been raised, for example, in a large cross-sectional study using FEV$_{25-75}$ z-score. That study concluded that FEV$_{25-75}$ did not provide additional information to current spirometric measures used in clinical practice, which contrasts with the close relationship demonstrated in our study. However, the study by Quanjer et al included a large and mixed population of participants including a variety of lung diseases. The lack of utility of a test in a general population does not negate its use in a selected one, a concept supported in the...
study of a highly selected population (AATD), where low FEV$_{25-75}$ z-score was associated with reduced lung function. In addition, further studies should evaluate whether low FEV$_{25-75}$ preceded the development of macroscopic emphysema, a classic component of the PiZZ genetic variant. A 10-year longitudinal study demonstrated that non-AATD patients with low FEV$_{25-75}$ z-score had a higher incidence rate of developing COPD than those with normal FEV$_{25-75}$ z-score (41.8% vs 7.4%, p<0.001). The authors used the same normality cut-off for as used in the current study. Considering that small airways dysfunction seems to precede AL and the fact that loss of >70% of small airways has to occur before COPD becomes detectable by FEV$_{1}$/FVC, patients with FEV$_{25-75}$ z-score<−0.8435 described by Kwon et al possibly had impairment in their small airways that would have worsened over time due to the continual exposure to risk factors, leading to the development of AL.

Our study provides evidence to support the use of FEV$_{25-75}$ (expressed as z-score) as an assessment tool in patients potentially at risk of developing COPD. We suggest that patients with FEV$_{25-75}$<0.8453 should be considered a phenotypic group that likely reflects early impairment in the small airways. This group of patients should be monitored and early preventive measures (most importantly, smoking cessation) should be objectively supported and encouraged especially when there is progression. In this group, the reduction of environmental-related exposure (ie, pollution, work related exposure and biomass fuel exposure) may also be beneficial in stabilising progression to COPD. Moreover, pharmacological treatments such as extra-fine particles inhalers may be of particular use in this group, as they achieve higher deposition in the small airways. However, this concept clearly requires further research to determine whether such treatments are of value for this group. Other measures of small airways have also demonstrated value in the early detection of COPD. In this study, we chose FEV$_{25-75}$ because of its availability already in routine physiological assessment.

Our study has limitations. It was a cross-sectional study but the value of FEV$_{25-75}$ as a monitoring tool has also been demonstrated longitudinally and our study provided a larger sample confirming the prevalence of low FEV$_{25-75}$ in smokers with and without AL. FEV$_{25-75}$ is a highly variable spirometric measure but we used FEV$_{25-75}$ z-score to optimise the interpretive accuracy. This was also a retrospective study, meaning that available data were limited to routine lung function tests, although this is more representative of the real-world approach to such strategies. Studies have shown that RV/TLC is also a potential marker for SAF. However, the data analysed in this study was limited to spirometric measures and did not include lung volumes such as RV and TLC. Therefore, further studies should evaluate whether low FEV$_{25-75}$ is associated with low RV/TLC. We pragmatically used z-score cut-off to define low FEV$_{25-75}$ which is different from the LLN for other lung function parameters. The ERS/ATS guidelines highlight that no satisfactory outcome-based thresholds for lung function have been defined and that further research is needed to establish a comprehensive disease-specific clinical approach to interpretation. The chosen cut-off for our study has also been used by others and shown to significantly predict COPD development, indicating it likely reflects early impairment in the small airways.

In conclusion, low FEV$_{25-75}$ z-score is a physiological feature present in patients with AL and also in symptomatic patients in the absence of AL. These findings highlight the potential importance of FEV$_{25-75}$ as a marker of small airways impairment, and importantly, in the detection of early pathological features of COPD. FEV$_{25-75}$ is part of routine lung function assessment, and therefore, closely monitoring patients with low FEV$_{25-75}$ and considering early interventions may be central to improving health and prognosis.

Author affiliations
1Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, UK
2Respiratory Therapy Department, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Alahsa, Saudi Arabia
3King Abdullah International Medical Research Center, Alahsa, Saudi Arabia
4Rehabilitation Health Sciences Department, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia
5Lung Function & Sleep Department, Respiratory Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
6Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK
7Acute Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Contributors NYA was the study’s guarantor, responsible for conducting the study, had access to the data, and controlled the decision to publish the study. NYA and ES designed and planned the study. NYA and MA analysed the data. NYA wrote the initial manuscript. ES, RAS and JS reviewed the data and revised the manuscript. All authors read and approved the final version of the manuscript.

Funding This study was conducted as part of PhD studentship for NYA. NYA is supported by King Saud bin Abdulaziz University for health sciences through the Saudi Arabian Cultural Bureau in the UK.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval The data study was approved by the Health Research Authority (HRA – project number 274729) and the South Birmingham Research Ethics Committee (Reference number 20/WM/0024).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. The lung function data used and evaluated during this study can be made available from the corresponding author, NYA, on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any errors and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID IDs
Nowal Y Alobaidi http://orcid.org/0000-0002-0609-5771
Mohammed Almeshari http://orcid.org/0000-0001-8449-9491
Elizabeth Sapey http://orcid.org/0000-0003-3454-5482

REFERENCES
1. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645–53.
2. Hogg JC, Macklem PT, Turbide WM. Site and nature of airway obstruction in chronic lung disease. N Engl J Med 1968;278:1355–60.
3. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011;365:1565–75.
4. Koel H-K, Vasilescu DM, Booth S, et al. Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study. Lancet Respir Med 2018;6:591–602.
5. Global Initiative for Chronic Obstructive Lung Disease. The global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease report. 2022. Available: https://goldcopd.org/2022-gold-reports/ [Accessed 21 Feb 2022].
6. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948.
7. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3–95-year age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324.
8. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1594–92.
9. Herpel LB, Kanner RE, Lee SM, et al. Variability of spirometry in chronic obstructive pulmonary disease: results from two clinical trials. Am J Respir Crit Care Med 2006;173:1106–13.
10. Pennock BE, Rogers RM, McCaffrey AM. Changes in measured mid-expiratory flow/forced expiratory volume in 1 second over time in COPD. Chest 2012;142:1396–43.
11. Bosken CH, Wiggs BR, Paré PD, et al. Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis 1990;142:563–70.
12. Gennennata S-A, Palamidas A, Karakontaki F, et al. Pathophysiology of evolution of small airways disease to overt COPD. COPD 2010;7:269–75.
13. Stockley JA, Ismail AM, Hughes SM, et al. Maximal mid-expiratory flow detects early lung disease in α1-antitrypsin deficiency. Eur Respir J 2012;40:1324.
14. Tsushima K, Sone S, Yoshikawa S, et al. Clinical differences in the global initiative for chronic obstructive lung disease stage G. Respir Med 2006;100:1360–7.
15. Mirsadraee M, Boskabady MH, Attaran D. Diagnosis of chronic obstructive pulmonary disease earlier than current global initiative for obstructive lung disease guidelines using a feasible spirometry parameter (maximal mid-expiratory flow/forced vital capacity). Chron Respir Dis 2013;10:191–6.
16. Boeck L, Genamer A, Nyilas S, et al. Single-breath washout tests to assess small airway disease in COPD. Chest 2016;150:1001–1007.
17. Verbanck S. Physiological measurement of the small airways. Respiraution 2012;84:177–88.
18. Oxojo H, Bake B, Wilhelmsen L. Ability of spirometry, flow-volume curves and the nitrogen closing volume test to detect smokers. A population study. Scand J Respir Dis 1977;58:90–96.
19. Kwon DS, Choi YJ, Kim TH, et al. FEF(25-75%) values in patients with normal lung function can predict the development of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2020;15:2913–21.
20. Bazzan E, Semenato U, Turato G, et al. Symptomatic smokers without COPD have physiological changes heralding the development of COPD. Eur J Open Res 2022;8: doi:10.1183/23120541.002002-2022. [Epub ahead of print: 27 06 2022].
21. Lee Y-H, Shin M-H, Kweon S-S, et al. Cumulative smoking exposure, duration of smoking cessation, and peripheral arterial disease in middle-aged and older Korean men. BMC Public Health 2011;11:94.
22. Sylvester KP, Clayton N, Clift I, et al. ARTP statement on pulmonary function testing 2020. BMJ Open Respir Res 2020;7:e000575.
23. Quanjer PH, Tammelung GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Workong Party standardization of lung function tests, European community for steel and coal. official statement of the European respiratory Society. Eur Respir J Suppl 1993;16:5–40.
24. Quanjer PH, PrettOJJ, Brazzale DJ, et al. Grading the severity of airways obstruction: new wine in new bottles. Eur Respir J 2014;43:505–12.
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289–300.
26. Tam A, Chung A, Wright JL, et al. Sex differences in airway remodeling in a mouse model of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2016;193:825–34.
27. Amoral AFS, Strachan DP, Burney PGJ, et al. Female smokers are at greater risk of airflow obstruction than male smokers. UK Biobank. Am J Respir Crit Care Med 2017;195:1226–35.
28. Martin TR, Castle RG, Fredberg JJ, et al. Airway size is related to sex but not lung size in normal adults. J Appl Physiol 1987;63:2042–7.
29. Sheel AW, Guenette JA, Yuan R, et al. Evidence for dysanapsis using computed tomographic imaging of the airways in older ex-smokers. J Appl Physiol 2009;107:1622–8.
30. Morris ZQ, Coz A, Starosta D. An isolated reduction of the FEV3/FVC ratio is an indicator of mild lung injury. Chest 2013;144:1117–23.
31. National Institute for Health and Care Excellence. NICE guidelines - Chronic obstructive pulmonary disease in over 16s: diagnosis and management, 2019. Available: https://www.nice.org.uk/guidance/ng115 [Accessed 21 Feb 2022].
32. Ejiofor S, Turner AM. Pharmacotherapies for COPD. Clin Med Insights Circ Res Pulm Med 2013;7:321–11.
33. Han MK, Ye W, Kim D-Y, et al. Design of the redefining therapy in early COPD study. Chronic Obstr Pulm Dis 2020;7:382–9.
34. Gelb AF, Yamamoto A, Verbeken EK, et al. Normal routine spirometry can mask COPD/Emphysema in symptomatic smokers. Chronic Obstr Pulm Dis 2021;8:124–34.
35. Quanjer PH, Weiner DJ, Pretto JJ, et al. Measurement of FEF25-75% and FEF75% does not contribute to clinical decision making. Eur Respir J 2014;43:1051.
36. Pirina P, Foschino Barbaro MP, Paleari D, et al. Small airway inflammation and extrathinal inhaled corticosteroids plus long-acting beta₂-agonists formulations in chronic obstructive pulmonary disease. Respir Med 2018;143:74–81.
37. van den Berge M, De Backer J, Van Holsbeke C, et al. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD, the value of inhaled corticosteroids. Respir Res 2021;22:191.
38. Usmani OS, Scicilione N, Mignot B, et al. Airway deposition of Extrafine inhaled triple therapy in patients with COPD: a model approach based on functional respiratory imaging computer simulations. Int J Chron Obstruct Pulmon Dis 2020;15:2433–40.
39. Piorunek T, Kostrzewska M, Stelmach-Mardas M, et al. Small airway obstruction in chronic obstructive pulmonary disease: potential parameters for early detection. Adv Exp Med Biol 2017;980:75–82.
40. Mahat B, Caumont-Prim A, Plantier L, et al. Relationships between respiratory and airway resistances and activity-related dyspnea in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2012;7:165–71.
41. Crisafulli E, Pisi R, Aiello M, et al. Prevalence of small-airway dysfunction among COPD patients with different gold stages and its role in the impact of disease. Respiraution 2017;93:32–41.
42. Li Y, Li X-Y, Yuan L-R, et al. Evaluation of small airway function and its application in patients with chronic obstructive pulmonary disease (review). Exp Ther Med 2021;22:1386.
43. Li K, Gao Y, Pan Z, et al. Influence of emphysema and air trapping heterogeneity on pulmonary function in patients with COPD. Int J Chron Obstruct Pulmon Dis 2019;14:2863–72.
44. Stanjevic S, Kaminsky DA, Miller M, ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2021;2011499.
Small airway function measured using forced expiratory flow between 25% and 75% of vital capacity and its relationship to airflow limitation in symptomatic ever-smokers: A cross-sectional study

Nowaf Y. Alobaidi, Mohammed A. Almeshari, James A. Stockley, Robert A. Stockley, Elizabeth Sapey

Online Supplement
# Supplementary Tables

Table E1. List of medications used in the included participants

| Variable               | Total        | Normal FEF<sub>25-75</sub>/AL- | Low FEF<sub>25-75</sub>/AL- | Low FEF<sub>25-75</sub>/AL+ |
|------------------------|--------------|---------------------------------|-----------------------------|-------------------------------|
|                        | n=1458       | n = 316                         | n = 335                     | n = 806                       |
| SABA                   | 891 (61.1)   | 128 (40.5)                      | 186 (55.7)<sup>*</sup>      | 576 (71.4)<sup>†</sup>       |
| SAMA                   | 51 (3.5)     | 2 (0.6)                         | 10 (3)                      | 39 (4.8)                      |
| SABA/SAMA              | 1 (0.1)      | 0 (0)                           | 0 (0)                       | 1 (0.1)                       |
| ICS                    | 85 (5.8)     | 17 (5.4)                        | 22 (6.6)                    | 45 (5.6)                      |
| LABA                   | 24 (1.6)     | 1 (0.3)                         | 3 (0.9)                     | 20 (2.5)                      |
| ICS/LABA               | 405 (27.8)   | 33 (10.4)                       | 70 (21)<sup>†</sup>        | 302 (37.4)<sup>†</sup>       |
| LAMA                   | 353 (24.2)   | 20 (6.3)                        | 47 (14.1)<sup>†</sup>      | 286 (35.4)<sup>†</sup>       |
| LABA/LAMA              | 36 (2.5)     | 2 (0.6)                         | 9 (2.7)                     | 25 (3.1)                      |
| ICS/LABA/LAMA          | 7 (0.5)      | 0 (0)                           | 0 (0)                       | 7 (0.9)                       |
| Systematic CS          | 55 (3.8)     | 2 (0.6)<sup>†</sup>             | 15 (4.5)                    | 38 (4.7)                      |
| Antibiotic             | 28 (1.9)     | 1 (0.3)                         | 8 (2.4)                     | 19 (2.4)                      |
| Montelukast            | 25 (1.7)     | 3 (0.9)                         | 4 (1.2)                     | 18 (2.2)                      |
| CV Medications         | 687 (47.1)   | 183 (57.9)<sup>†</sup>          | 160 (47.9)                  | 343 (42.5)                    |
| GI Medications         | 381 (26.1)   | 97 (30.7)                       | 96 (28.7)                   | 187 (23.2)<sup>‡</sup>       |
| Domiciliary Oxygen     | 19 (1.3)     | 2 (0.6)                         | 5 (1.5)                     | 12 (1.5)                      |
| Mucolytic              | 101 (6.9)    | 3 (0.9)                         | 14 (4.2)<sup>†</sup>       | 88 (10.9)<sup>†</sup>        |
| Theophylline           | 15 (1.0)     | 0 (0)                           | 1 (0.3)                     | 14 (1.7)                      |

**Legend:** Data is presented in n (%); <sup>*</sup> Significantly different from group 1; <sup>†</sup> Significantly different from group 2; <sup>‡</sup> Significantly different from group 3. Significance level was set at P<0.05

**Abbreviations:** FEF<sub>25-75</sub>, forced expiratory flow between 25% and 75% of vital capacity; AL, airflow limitation; SABA, short-acting beta-2 agonist; SAMA, short-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting beta-2 agonist; LAMA, long-acting muscarinic antagonist; CS, corticosteroid; CV, Cardiovascular; GI, gastrointestinal.
Table E3. The relationship of FEF<sub>25-75</sub> and FEF<sub>25-75</sub>/FVC with spirometric measures (n=1458)

| Spirometric measures | FEF<sub>25-75</sub> % predicted | FEF<sub>25-75</sub>/FVC | r<sup>2</sup> | P value | r<sup>2</sup> | P value |
|----------------------|----------------------------------|-------------------------|--------------|---------|--------------|---------|
| FEV<sub>1</sub> (% predicted) | 0.71 | <0.001 | 0.47 | <0.001 | 0.47 | <0.001 |
| FVC (% predicted) | 0.13 | <0.001 | 0.006 | <0.001 | 0.006 | <0.001 |
| FEV<sub>1</sub>/FVC (%) | 0.83 | <0.001 | 0.92 | <0.001 | 0.92 | <0.001 |
| FEV<sub>3</sub>/FVC (%) | 0.70 | <0.001 | 0.82 | <0.001 | 0.82 | <0.001 |

**Legend:** This table presents the relationship of FEF<sub>25-75</sub> % predicted and FEF<sub>25-75</sub>/FVC with other spirometric measures. The relationship was assessed using curvilinear regression analysis. **Abbreviations:** FEF<sub>25-75</sub>, forced expiratory flow between 25% and 75% of vital capacity; FEV<sub>1</sub>, forced expiratory volume in the first second; FVC, forced vital capacity; FEV<sub>3</sub>, forced expiratory volume in three seconds.
Supplementary Figures

Figure E1. Distribution of % predicted or ratio of spirometric measures across study groups.

Legend: A box plot demonstrating the distribution of the % predicted or ratio of spirometric measures across study groups. The plot shows median, interquartile range, minimum and maximum. A) The distribution of...
FEF\textsubscript{25-75} % predicted across groups. B) The distribution of FEF\textsubscript{25-75}/FVC ratio across groups. C) The distribution of FEV\textsubscript{1} % predicted across groups. D) The distribution of FVC % predicted across groups. E) The distribution of FEV\textsubscript{1}/FVC ratio across groups. F) The distribution of FEV\textsubscript{3}/FVC ratio across groups. For groups’ comparisons, Kruskal-Wallis H test was performed, and for statistically significant test, a post-hoc Dunn’s test was applied. The presented $P$ values were adjusted using the Bonferroni method to account for multiple comparisons. For figures A and E, statistical test was only done for differences between groups where a definition did cause the variable to differ, and the reported $p$-values are for the Mann-Whitney U test. For figures B, C, D and F, the presented $p$-values are for post-hoc Dunn’s test, and the Kruskal Wallis tests $p$-values for all figures were $<0.001$.

**Abbreviations:** FEV\textsubscript{1}, forced expiratory volume in 1 second; FVC, forced vital capacity; FEF\textsubscript{25-75}, forced expiratory flow between 25% and 75% of vital capacity; FEV\textsubscript{3}, forced expiratory volume in the first 3 seconds; AL, airflow limitation; NS, not significant.
Figure E2. Distribution of FEF_{25-75} and FEF_{25-75}/FVC across AL severity.

Legend: A box plot demonstrating the distribution of FEF_{25-75} and FEF_{25-75}/FVC across AL severity. The plot shows median, interquartile range, minimum and maximum. A) The distribution of FEF_{25-75} % predicted across severity. B) The distribution of FEF_{25-75}/FVC ratio across severity. AL severity was assessed using FEV_{1} z-score. For groups’ comparisons, Kruskal-Wallis H tests was performed, and for statistically significant test, a
post-hoc Dunn's test was applied. The presented $P$ values were adjusted using the Bonferroni method to account for multiple comparisons. The $p$-values for Kruskal-Wallis $H$ tests for both figures were <0.001.

**Abbreviations:** FEF$_{25-75}$, forced expiratory flow between 25% and 75% of vital capacity; FVC, forced vital capacity; NS, not significant; AL, airflow limitation.
Figure E3. FEV\(_1\) % predicted and FEV\(_1\)/FVC plotted against FEF\(_{25-75}\) % predicted.

**Legend:** A) A scatter plot showing the relationship between FEF\(_{25-75}\) % predicted and FEV\(_1\) % predicted. B) A scatter plot showing the relationship between FEF\(_{25-75}\) % predicted and FEV\(_1\)/FVC %. The coefficient of determination (r\(^2\)) for the curvilinear regression is shown in the figure along with its P value.

**Abbreviations:** FEF\(_{25-75}\), forced expiratory flow between 25\% and 75\% of vital capacity; FEV\(_1\), forced expired volume in the first second; FVC, forced vital capacity.
Figure E4. FEV₁ % predicted and FEV₁/FVC plotted against FEF₂₅-₇₅/FVC.

Legend: A) A scatter plot showing the relationship between FEF₂₅-₇₅/FVC and FEV₁ % predicted. B) A scatter plot showing the relationship between FEF₂₅-₇₅/FVC and FEV₁/FVC. The coefficient of determination (r²) for the curvilinear regression is shown in the figure along with its P value.

Abbreviations: FEF₂₅-₇₅, forced expiratory flow between 25% and 75% of vital capacity; FEV₁, forced expired volume in the first second; FVC, forced vital capacity.